- Ongoing, recruitingTherapeutic confirmatory (Phase III)
A phase IIIb, multi-center, open-label, treatment optimization study of oral asciminib in patients with Chronic Myelogenous Leukemia in chronic phase (CMLCP) previously treated with 2 or more tyrosine kinase inhibitors
This study is looking at a new way to use an existing medicine called asciminib for people with a type of blood cancer called Chronic Myelogenous Leukemia (CML). It's for patients who have already tried two or more other CML treatments. The main goal is to see how well asciminib works to control the cancer.
For: Chronic Myelogenous Leukemia in chronic phase (CML-CP)Spain · France · Poland - Active not recruitingPHASE3
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
This study looks at a new medicine called asciminib for adults with a type of blood cancer called CML. Researchers want to see if it works better than other standard CML treatments. It's for people recently diagnosed who haven't had treatment yet.
For: Chronic Myeloid Leukemia (CML) Philadelphia Chromosome PositiveUnited States · Australia · Austria - Active not recruitingPHASE3
A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)
This study compared two oral medications, asciminib and nilotinib, for adults newly diagnosed with a type of blood cancer called Philadelphia chromosome-positive chronic myeloid leukemia (CML). It looked at how well people tolerated each drug.
For: Philadelphia Chromosome-Positive Chronic Myeloid LeukemiaUnited States · Argentina · Bulgaria